162 related articles for article (PubMed ID: 32996176)
21. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
[TBL] [Abstract][Full Text] [Related]
22. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
23. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
24. Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.
Mayor-Ibarguren A; Roldán-Puchalt MC; Gómez-Fernández C; Albízuri-Prado F; Álvarez-Escola C
JAMA Dermatol; 2016 Jan; 152(1):109-11. PubMed ID: 26444320
[No Abstract] [Full Text] [Related]
25. Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy.
Cosentini D; Grisanti S; Hadoux J; Libè R; Frigerio M; Laganà M; Deschamps F; Zamparini M; Lamartina L; Pedersini R; Valsecchi C; Maroldi R; Al Ghuzlan A; Terzolo M; Gasparotti R; Baudin E; Berruti A
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2167-e2176. PubMed ID: 34905056
[TBL] [Abstract][Full Text] [Related]
26. Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.
Salenave S; Bernard V; Do Cao C; Guignat L; Bachelot A; Leboulleux S; Droumaguet C; Bry-Gauillard H; Pierre P; Crinière L; Santulli P; Touraine P; Chanson P; Schlumberger M; Maiter D; Baudin E; Young J
Eur J Endocrinol; 2015 Feb; 172(2):141-9. PubMed ID: 25411236
[TBL] [Abstract][Full Text] [Related]
27. Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
Szkodziak PR; Czuczwar P; Woźniak S; Szkodziak F; Paszkowski T
Ginekol Pol; 2017; 88(10):576-577. PubMed ID: 29192420
[TBL] [Abstract][Full Text] [Related]
28. No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma.
Ederhy S; Cohen A; Dufaitre G; Chaderevian R; Abbas H; Bertagna X; Libé R
J Endocrinol Invest; 2012 Nov; 35(10):911-4. PubMed ID: 23013780
[TBL] [Abstract][Full Text] [Related]
29. Adjunctive treatment of adrenocortical carcinoma.
Terzolo M; Berruti A
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
[TBL] [Abstract][Full Text] [Related]
30. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
[TBL] [Abstract][Full Text] [Related]
31. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
32. [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
Yamashita D; Hanai T; Onuki T; Suzuki K; Nakayama T
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):12-17. PubMed ID: 31956212
[TBL] [Abstract][Full Text] [Related]
33. Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma.
Tada H; Nohara A; Kawashiri MA; Inazu A; Mabuchi H; Yamagishi M
J Atheroscler Thromb; 2014; 21(12):1326-9. PubMed ID: 25392159
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant mitotane in adrenocortical carcinoma.
Bertherat J; Coste J; Bertagna X
N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
[No Abstract] [Full Text] [Related]
35. How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives.
Steenaard RV; Ettaieb MHT; Kerkhofs TMA; Haak HR
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):677-683. PubMed ID: 33886381
[TBL] [Abstract][Full Text] [Related]
36. Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth.
Trotta F; Avena P; Chimento A; Rago V; De Luca A; Sculco S; Nocito MC; Malivindi R; Fallo F; Pezzani R; Pilon C; Lasorsa FM; Barile SN; Palmieri L; Lerario AM; Pezzi V; Casaburi I; Sirianni R
Mol Cancer Ther; 2020 Sep; 19(9):1909-1921. PubMed ID: 32546662
[TBL] [Abstract][Full Text] [Related]
37. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant mitotane in adrenocortical carcinoma.
Dickstein G; Shechner C; Nativ O
N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
[No Abstract] [Full Text] [Related]
39. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant mitotane in adrenocortical carcinoma.
Lee JE
N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
